On August 6, 2014 Vernalis and Servier reported the achievement of two milestones in their oncology drug discovery collaborations, triggering a payment of €0.75m to Vernalis (Press release, Servier, AUG 6, 2014, View Source [SID:1234508827]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Vernalis and Servier have been working in partnership since initiating their first collaboration in May 2007. The collaborations utilise Vernalis’ proprietary fragment and structure-based drug discovery platform on a number of oncology targets, of which only Bcl-2 has been disclosed. Under the collaborations, Vernalis receives fees and a share in the future success of any products in the form of development milestones and royalties on sales. Financial terms are not disclosed.

Ian Garland, CEO of Vernalis, commented: "We are delighted to achieve these milestones, recognising our very successful partnership with Servier, and we look forward to further success from this relationship."

Jean Pierre Abastado, Head of the Center for Therapeutic Innovation in Oncology at Servier, said: "Small molecules tailored against specific targets can have very high therapeutic potential. These new successes with Vernalis demonstrate the ability of this partnership to identify and characterize promising compounds which further extend Servier’s portfolio to treat cancer patients."